SNNLive interview with J.J. Finkelstein, President & CEO of RegeneRx Biopharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY.

Watch the video interview.

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

October 28, 2015
RegeneRx Analyst Report Update Issued by SeeThruEquity, LLC

October 23, 2015
RegeneRx Updates on Asian Ophthalmic Clinical Trials

October 21, 2015
RegeneRx Updates on U.S. Ophthalmic Clinical Trials

October 20, 2015
RegeneRx's TB4 Shown to Significantly Limit Brain Damage After Stroke by Upregulating microRNA-200a

September 30, 2015
RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

September 21, 2015
RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

September 16, 2015
RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259

September 2, 2015
RegeneRx to Present at Rodman & Renshaw Global Investment Conference